Rick Shinto Continues To Improve InnovaCare Health

Since 2012 InnovaCare Health has been under the leadership of company CEO Dr. Richard Shinto. Rick Shinto’s over 20 years in the healthcare industry has made him an authority in managed healthcare. He brings years of technical experience as well as proven leadership skills to InnovaCare in his position as company president. InnovaCare Health is a leading provider of managed healthcare services in North America, including Medicare Advantage and Medicaid programs. InnovaCare and their affiliates remain dedicated to bringing quality healthcare to its many clients, located throughout North America and Puerto Rico.

Before joining InnovaCare, Rick Shinto served in several other prestigious healthcare positions. He was the Chief Medical Officer for Cal Optima Health, the Chief Medical Officer for Medical Pathways Management and served as president and CEO of Aveta Inc. During his tenure with Aveta Rick was awarded a very prestigious award, he was named the recipient of the Ernst & Young Entrepreneur of the year. The awarded given to individuals who have displayed a commitment to excellence in their respective fields. Read this article at Open Minds.

Rick Shinto believes teamwork and transparency are behind the success of InnovaCare. Excellent communication and a clear vision of the future coupled with a proper working relationship are what it takes to be successful in the future. Rick Shinto and InnovaCare Health are redefining the management of managed healthcare in today’s ever-changing healthcare environment. He is considered the driving force behind the ongoing changes and improvements at InnovaCare that will make it possible for the company to expand into other markets in the future. All this will ultimately lead to better patient benefits and care.

In Puerto Rico, InnovaCare Health works out of two affiliates. The company operates MMM Healthcare Inc. and PMC Medicare Choice Inc.; both programs offer quality medical care programs designed to give their clients both physical and emotional wellbeing. The two affiliates enjoy an approval rate of 90 percent and have received an NCQA accreditation. To be considered for this certification, a company must meet or exceed the recognized requirements of a quality healthcare program. Read more about Rick Shinto on BusinessWire.Com

Rick Shinto has a B.S. degree from the University of California, earned his medical degree at the University of New York and received his M.B.A. from the University of Redlands. After graduation, Rick began his career as a pulmonologist in Southern California. He has authored many articles and received several awards for his work in the managed healthcare industry.

Could This be the Awaited Breakthrough for Treating Multiple Sclerosis?

The Medicine profession is considered technical. Neurologists such as Dr. Shiva Gopal Vasishita, for instance, are specifically trained in the diagnosis and treatment of nervous system disorders including ailments of the brain, spinal cord, nerves, and muscles. They are subjected to a rigorous education system meant to build their capacity of the complexities that await them in neurology.

Dr. Shiva Gopal Vasishita happens to be one of the practicing neurologists we have today. He graduated from Government Medical College in 1979 and has been practicing both neurology and psychiatry for 40years now in Voorhees, New Jersey. In his line of work, Dr. Shiva plays a vital role in explaining the mechanisms of a traumatic brain injury, the results of clinical examination and the significance of diagnostic test results.

On 1st February 2017, the National Institute of Health disclosed that evidence from recent trials suggested that high-dose immunosuppressive therapy then a transplant of a person’s blood- forming stem cells had the ability to induce sustained remission of relapsing-remitting multiple sclerosis. 69 percent of the trial participants survived without experiencing progression of disability, relapsing of MS syndrome or new brain lesions five years later after receiving high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT). The participants did not need any MS medication after receiving HDIT/HCT.

The trial that was sponsored by the National Institute of Allergy and Infectious Diseases (NIAD) published the final five-year results in Neurology- the medical journal of the American Academy of Neurology on 1st February.

The possibility of a one-time HDIT/HCT treatment being substantially more effective than long-term treatment with medications for Multiple Sclerosis is great news for neurologists such as Dr. Shiva who are committed to getting breakthroughs in solving brain diseases.